RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/27132628/ below:

Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity

doi: 10.1016/j.amepre.2016.03.017. Epub 2016 Apr 28. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity Jane J Kim², Elisabeth F Beaber³, Yingye Zheng⁴, Andrea Burnett-Hartman⁵, Jessica Chubak⁶, Nirupa R Ghai⁷, Dale McLerran³, Nancy Breen⁸, Emily F Conant⁹, Berta M Geller¹⁰, Beverly B Green⁶, Carrie N Klabunde¹¹, Stephen Inrig¹², Celette Sugg Skinner¹³, Virginia P Quinn⁷, Jennifer S Haas¹⁴, Mitchell Schnall⁹, Carolyn M Rutter¹⁵, William E Barlow¹⁶, Douglas A Corley¹⁷, Katrina Armstrong¹⁸, Chyke A Doubeni¹⁹; PROSPR consortium

Affiliations

¹ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: amccarthy8@partners.org.
² Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁴ Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁵ Division of Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington; Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
⁶ Group Health Research Institute, Seattle, Washington.
⁷ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
⁸ Health Systems and Interventions Research Branch, National Cancer Institute, Bethesda, Maryland.
⁹ Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
¹⁰ Department of Family Medicine, University of Vermont, Burlington, Vermont.
¹¹ Office of Disease Prevention, NIH, Bethesda, Maryland.
¹² Department of Health Policy and History of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Health Policy and Management, Mount Saint Mary's University, Los Angeles, California.
¹³ Department of Clinical Science and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
¹⁴ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
¹⁵ RAND Corporation, Santa Monica, California.
¹⁶ Department of Biostatistics, University of Washington, Seattle, Washington.
¹⁷ Department of Gastroenterology, Kaiser Permanente Northern California, Oakland, California.
¹⁸ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
¹⁹ Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 27132628
PMCID: PMC5030116
DOI: 10.1016/j.amepre.2016.03.017

Item in Clipboard

Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity

Anne Marie McCarthy et al. Am J Prev Med. 2016 Oct.

doi: 10.1016/j.amepre.2016.03.017. Epub 2016 Apr 28. Authors Anne Marie McCarthy¹, Jane J Kim², Elisabeth F Beaber³, Yingye Zheng⁴, Andrea Burnett-Hartman⁵, Jessica Chubak⁶, Nirupa R Ghai⁷, Dale McLerran³, Nancy Breen⁸, Emily F Conant⁹, Berta M Geller¹⁰, Beverly B Green⁶, Carrie N Klabunde¹¹, Stephen Inrig¹², Celette Sugg Skinner¹³, Virginia P Quinn⁷, Jennifer S Haas¹⁴, Mitchell Schnall⁹, Carolyn M Rutter¹⁵, William E Barlow¹⁶, Douglas A Corley¹⁷, Katrina Armstrong¹⁸, Chyke A Doubeni¹⁹; PROSPR consortium Affiliations

¹ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: amccarthy8@partners.org.
² Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁴ Department of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁵ Division of Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington; Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
⁶ Group Health Research Institute, Seattle, Washington.
⁷ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
⁸ Health Systems and Interventions Research Branch, National Cancer Institute, Bethesda, Maryland.
⁹ Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
¹⁰ Department of Family Medicine, University of Vermont, Burlington, Vermont.
¹¹ Office of Disease Prevention, NIH, Bethesda, Maryland.
¹² Department of Health Policy and History of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Health Policy and Management, Mount Saint Mary's University, Los Angeles, California.
¹³ Department of Clinical Science and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
¹⁴ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
¹⁵ RAND Corporation, Santa Monica, California.
¹⁶ Department of Biostatistics, University of Washington, Seattle, Washington.
¹⁷ Department of Gastroenterology, Kaiser Permanente Northern California, Oakland, California.
¹⁸ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
¹⁹ Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 27132628
PMCID: PMC5030116
DOI: 10.1016/j.amepre.2016.03.017

Item in Clipboard

Abstract

Introduction: Timely follow-up of abnormal tests is critical to the effectiveness of cancer screening, but may vary by screening test, healthcare system, and sociodemographic group.

Methods: Timely follow-up of abnormal mammogram and fecal occult blood testing or fecal immunochemical tests (FOBT/FIT) were compared by race/ethnicity using Population-Based Research Optimizing Screening through Personalized Regimens consortium data. Participants were women with an abnormal mammogram (aged 40-75 years) or FOBT/FIT (aged 50-75 years) in 2010-2012. Analyses were performed in 2015. Timely follow-up was defined as colonoscopy ≤3 months following positive FOBT/FIT; additional imaging or biopsy ≤3 months following Breast Imaging Reporting and Data System Category 0, 4, or 5 mammograms; or ≤9 months following Category 3 mammograms. Logistic regression was used to model receipt of timely follow-up adjusting for study site, age, year, insurance, and income.

Results: Among 166,602 mammograms, 10.7% were abnormal; among 566,781 FOBT/FITs, 4.3% were abnormal. Nearly 96% of patients with abnormal mammograms received timely follow-up versus 68% with abnormal FOBT/FIT. There was greater variability in receipt of follow-up across healthcare systems for positive FOBT/FIT than for abnormal mammograms. For mammography, black women were less likely than whites to receive timely follow-up (91.8% vs 96.0%, OR=0.71, 95% CI=0.51, 0.97). For FOBT/FIT, Hispanics were more likely than whites to receive timely follow-up than whites (70.0% vs 67.6%, OR=1.12, 95% CI=1.04, 1.21).

Conclusions: Timely follow-up among women was more likely for abnormal mammograms than FOBT/FITs, with small variations in follow-up rates by race/ethnicity and larger variation across healthcare systems.

PubMed Disclaimer